May 23, 2018 | Anti-METH ch-mAb7F9, General News
– IXT-m200 is InterveXion’s lead program in treating methamphetamine abuse – STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users Little Rock, AR – InterveXion Therapeutics, a...
May 10, 2018 | Anti-METH ch-mAb7F9, General News
STAMPOUT: Phase 2 proof-of-concept trial to test effects of first-in-class anti-methamphetamine antibody in methamphetamine users Little Rock, AR – InterveXion announces the enrollment of the first patient in STAMPOUT, the first trial in methamphetamine users of the...
Jan 4, 2018 | Anti-METH ch-mAb7F9, General News
Addresses Major Global Unmet Medical Need in Addiction Therapy Lead Asset, IXT-m200, has Received US FDA Fast-Track Designation IXT-m200 Advancing into Phase 2 Clinical POC Study in 1H18 Parallel Phase 3-Enabling Multiple Dose Clinical Study Initiating in 1H18 Little...
Oct 10, 2017 | Anti-METH ch-mAb7F9, General News, Grants
Little Rock, AR – InterveXion Therapeutics has received a federal grant to fund a second clinical study of IXT-m200, a monoclonal antibody designed to treat methamphetamine abuse. The clinical trial, called STAMPOUT, will be a Phase 2a, parallel-group,...
Jun 20, 2017 | Anti-METH ch-mAb7F9, General News
Little Rock, AR – Following the successful completion of Phase 1 clinical safety evaluation for the novel anti-methamphetamine antibody IXT-m200 (ch-mAb7F9), InterveXion has announced plans to continue clinical development of this agent. The STAMPOUT study will...
Jan 15, 2016 | Anti-METH ch-mAb7F9, General News, Uncategorized
Little Rock, AR – InterveXion Therapeutics, a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IXT-m200, also known as ch-mAb7F9, an investigational drug candidate for the...
Jan 29, 2015 | Anti-METH ch-mAb7F9, Anti-METH Vaccine, General News, Grants, Uncategorized
LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break...
Jan 5, 2015 | Anti-METH ch-mAb7F9, General News, Uncategorized
The company is pleased to report publication of the results of the first human study of ch-mAb7F9. The paper was published in the journal Mabs in early November. Abstract – This first-in-human study examined the safety and pharmacokinetics of ch-mAb7F9, an...
Nov 20, 2014 | Anti-METH ch-mAb7F9, General News, Uncategorized
A new manuscript published by UAMS describes the shortened duration of repeated METH dose effects in rats over a month following administration of mAb7F9. Abstract – This study assessed clinical scenarios of continuing monoclonal antibody (mAb) treatment for (+)-...
Nov 20, 2014 | Anti-METH ch-mAb7F9, General News, Uncategorized
InterveXion and UAMS have published a new manuscript describing the effects of two monoclonal antibodies designed to treat METH abuse. The studies compare the two antibodies and describe the factors that resulted in the choice of mAb7F9 for clinical development....
Recent Comments